Τόμος 20 (2006) – Τεύχος 2 – Άρθρο 32 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 25 (2006) – Issue 2 – Article 32 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Heparin activity-assay of liposomal formulations
Author Nikolaos Dietis

Scientific Advisor Lavipharm Hellas, Bsc Pharmacology, Univ. of Portsmouth, Halkis 25 & Laertou 27, Patriarxika Pylaias, Wallbox: 60147, Thessaloniki, Greece

Citation Dietis, N.: Heparin activity-assay of liposomal formulations, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 150-152 (2006)
Publication Date Accepted for publication: 19-20 May 2006
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) 

pharmakonpress[at]pharmakonpress[.]gr

Keywords Liposomes, heparin, assay, encapsulation, antithrombin.
Other Terms review article
Summary It is very important for a liposomal formulation that the encapsulated substance will be active upon release from the vesicle. Chemical reactions between the drug and its liposome carrier or the active site of the drug may result in an inactive form of the drug that will have no desirable effects whatsoever. The heparin activity assay was carried out in order to determine: a) the activity of the liposome-encapsulated heparin and b) the concentration of heparin encapsulated an alternative strategy of using liposome lysis with triton. The assay is based on the inhibitory effect of antithrombin III (ATiii) on the reaction between factor Xa and factor Xa substrate. This reaction yields a yellowish solution in which the intensity of the color is irreversible to the inhibition of ATiii. The activity of heparin, of which the presence enhances the inhibitory effect of ATiii, was able to be determined by the intensity of the resulted color of the solution. Blank wells (absent heparin) were used in order to determine the background absorbance (noise). A standard curve was produced relating the absorbance (reaction yield) with heparin activity by using free heparin. Two different kinds of liposomes were also used for this assay. One containing phosphatidic acid (used with cholesterol and lecithin, denoted PA) and the other containing stearylamine (used with phospatidylcholine and cholesterol, denoted ST). Lysed and non-lysed liposomes were used to determine the activity of encapsulated heparin after release. The results showed clearly that encapsulated heparin detained its activity after liposomal lysis. However there was also an activity of non- lysed liposomal heparin which could be attributed to the heparin attached to the outside of the liposomal structure. The supernatants extracted from liposomal centrifugations were also measured for their absorbance in order to confirm their heparin-activity. Results also confirmed the theory of coated liposomal heparin.
References 1. Knight C.G., et al.: Liposomes as carriers of antiarthritic agents. Annual NY Academic Science, 446, 415-428 (1985)

2. Fryer A., et al.: Selective 0-disulphation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J. Pharmacol. Experim. Ther. 282: 202-219 (1997)

3. Fischer A.M., et al.: The stability of heparin-coated liposomes in plasma and their effect on its coagulation. Colloids and Surfaces B. Biointerfaces 10: 205-215 (1998)

4. Kim T.D., et al.: Metabolism of liposome-encapsulated heparin. Thromb. Res. 56: 369-376 (1989)

5. Kim T.D., et al.: Studies on liposome-encapsulated heparin. Thromb. Res. 43: 603-612 (1986)

6. New R.R.C.: Liposomes a practical approach. 0xford Univ. Press, New York, 1990

7. Lane D.A.: et al.: Anticoagulant activities of heparin oligosaccharides and their neutralization by PF4. Biochem. J. 218: 725 (1984)

8. Brown W.V., et al.: Heparin, lipoproteins and lipoprotein lipase. In: (Lundblad R.L., et al., eds) Chemistry and Biology of Heparin, New York, 1981

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

 

Bookmark the permalink.

Comments are closed.